ABCB1 C3435T

This study showed that the ABCB1 C3435T homozygous allele genotype (TT) is associated with increased MTX-related toxicities (leukopenia, neutropenia and oral mucositis). These results may help to distinguish pediatric ALL patients with a relatively high risk of MTX-related toxicities before HD-MTX infusion and optimize MTX treatment.

Complementing the existing criteria for pediatric ALL risk groups with pharmacogenetic indicators will allow further individualization of therapy.

Conclusions The homozygous mutant TT genotypes (C1236T and C3435T) and heterozygous CT genotypes (C1236T) showed significant association to chemo-induced toxicity (hematological toxicity, nausea, vomiting, alopecia) in patients underwent anthracycline and taxane. Hence, these SNPs could serve as predictive markers to mitigate chemotherapy's adverse effects and optimize treatment to reduce the grade of toxicity and improves patients quality of life.

Models that include both genetic and non-genetic determinants of ADRs of TAM may further improve the prediction of individual response to tamoxifen.

As the findings indicate, lung cancer and control groups demonstrate significantly different patterns of -129/1236/2677/3435 haplotype distribution; T-T-T-T haplotype contributes to NSCLC susceptibility, and this effect is probably mainly dependent on C3435T. So far, similar studies were published in other populations.

A slight trend can be observed in subjects with mutated genotype of ABCB1 C3435T, C1236T and G2677T/A polymorphisms.CONCLUSIONSCLL treatment has a high rate of ADR, the main risk being bleeding. So far, polymorphisms in enzymes and transporters involved in the ibrutinib pathway have not been shown to affect the incidence of ADR in CLL patients, probably due to the small sample size of our study.In addition to increasing the sample size, steady-state plasma concentrations of ibrutinib will be measured in order to correlate drug levels with polymorphisms in the genes analyzed and the incidence of ADR.

However, they may not be the critical ones when it comes to risk or recovery assessment. Consequently, they may not be treated as reliable prognostic or predictive markers in breast cancer patients' evaluation, which supports the previous findings and current knowledge.

Indonesia breast cancer patients who underwent three cycles of chemotherapy demonstrated susceptibility to hematological toxicity by developing side effects such as anemia and neutropenia. However, no relationship was found between hematological toxicity and ABCB1 and GSTP1 polymorphisms.

In conclusion, we have found that the overexpression of the ABCB1 gene, as well as the presence of the TT genotype of the C3435T SNP, contributes to a worse prognosis in AML.

The early clinical response and its association with SNPs in the ABCB1 transporter are preserved until the pathological response to neoadjuvant chemotherapy; therefore, it could be used as a predictor of chemoresistance in locally advanced breast cancer patients of the Mexican population.

The current study provides preliminary evidence of a significant association between variant TT genotype and increased B-ALL risk. Also, results suggest that ABCB1 3435TT genotype increases imatinib resistance in CML and influence therapeutic outcome in B-ALL.

This review revealed more systematic pharmacogenomics of genes involved in the metabolism and transport besides CYP2D6, are required to optimize the genotyping strategies and guide the personalized tamoxifen therapy in Asian populations.

The plasma levels of docetaxel were significantly influenced by the SNP C1236T of ABCB1 gene coding for the MDR1 transporter (P-glycoprotein). The plasma levels of docetaxel were also found to influence its therapeutic effect.

For SNP T129C, all subjects showed normal (TT) genotype. There was no significant association between ABCB1 3435C>T and 129T>C polymorphisms with CRC risk.

Japanese patients had significantly less good response to 5-fluorouracil/cisplatin chemotherapy. The influence of the three SNPs on response varied between patients from Japan and Germany. Different expressions of ERCC1 and ABCB1 SNPs of Japanese patients compared with the German patients partially explain the different response.